Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Assets (2016 - 2025)

Spyre Therapeutics' Current Assets history spans 11 years, with the latest figure at $777.8 million for Q4 2025.

  • For Q4 2025, Current Assets rose 27.82% year-over-year to $777.8 million; the TTM value through Dec 2025 reached $777.8 million, up 27.82%, while the annual FY2025 figure was $777.8 million, 27.82% up from the prior year.
  • Current Assets reached $777.8 million in Q4 2025 per SYRE's latest filing, up from $504.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $777.8 million in Q4 2025 to a low of $44.4 million in Q1 2023.
  • Average Current Assets over 5 years is $299.6 million, with a median of $222.9 million recorded in 2023.
  • Peak YoY movement for Current Assets: plummeted 52.05% in 2022, then surged 998.08% in 2024.
  • A 5-year view of Current Assets shows it stood at $98.9 million in 2021, then plummeted by 37.04% to $62.3 million in 2022, then skyrocketed by 448.57% to $341.5 million in 2023, then soared by 78.16% to $608.5 million in 2024, then rose by 27.82% to $777.8 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Current Assets are $777.8 million (Q4 2025), $504.6 million (Q3 2025), and $538.8 million (Q2 2025).